Get In Touch
ADO-TRASTUZUMAB EMTANSINE
ROCHE PRODUCTS INDIA PVT LTD
Advanced and metastatic breast cancer
1 VIAL(s)
Injection
Kadcyla 100 mg Injection is a targeted cancer therapy that contains the active ingredient Ado-Trastuzumab emtansine, specifically used for the treatment of HER2-positive breast cancer. It is prescribed for patients whose cancer has either spread to other parts of the body (metastatic breast cancer) or has not responded adequately to previous treatments. Kadcyla is a unique combination of two components—trastuzumab, a monoclonal antibody that targets HER2 receptors on cancer cells, and emtansine, a chemotherapy agent that works to destroy those cells. By directly targeting HER2-positive cancer cells, this medicine helps slow down tumor growth and improve treatment outcomes. It is also used in both early and advanced stages of breast cancer, especially in cases where the disease recurs within six months after chemotherapy.
Patients with residual cancer after chemotherapy and HER2-targeted therapy may have a higher risk of disease progression, making Kadcyla an important treatment option in such cases. While the medication is generally well tolerated and does not significantly affect kidney function, patients should remain alert for potential side effects. Some individuals may experience mild symptoms such as nausea, vomiting, diarrhea, or hair loss, while rare cases of infusion-related reactions or allergic responses may occur. It is important to report any unusual symptoms, including bleeding or severe reactions, to a healthcare provider immediately. Regular monitoring and medical supervision help ensure the safe and effective use of Kadcyla 100 mg Injection.
Kadcyla 100 mg Injection is primarily used in the treatment of HER2-positive cancers, especially in patients with advanced and metastatic breast cancer, where the cancer has spread beyond the breast to other parts of the body. It is also used in cases where the disease has not responded adequately to previous therapies, helping to control tumor growth and improve patient outcomes. In addition, Kadcyla may be used in the management of metastatic gastric (stomach) cancer that overexpresses the HER2 protein, offering a targeted treatment approach for better disease control.
Like other anticancer medicines, Kadcyla 100 mg Injection may cause side effects, which can be mild or serious depending on the patient’s condition and response to treatment.
If you experience any severe or unusual symptoms, seek immediate medical attention.
1. Do not use if you are allergic to Ado-Trastuzumab emtansine or any of its components.
2. May cause liver toxicity; regular liver function monitoring is required.
3. Can lead to low platelet count (thrombocytopenia), increasing the risk of bleeding
4. Use with caution in patients with heart problems, as it may affect heart function.
5. Infusion-related or allergic reactions may occur during or after administration.
6. Not recommended during pregnancy, as it may harm the unborn baby; use effective contraception.
7. Inform your doctor about all medications, supplements, or medical conditions before starting treatment.
8. Store in a refrigerator (2°C to 8°C).
9. Do not freeze or shake the vial.
10. Keep in the original packaging to protect from light.
Kadcyla 100 mg Injection is used for the treatment of HER2-positive breast cancer, especially in patients with advanced or metastatic disease or those who have not responded to previous therapies.
Kadcyla 100 mg Injection combines trastuzumab (a targeted antibody) with emtansine (a chemotherapy agent) to directly attack HER2-positive cancer cells, helping to stop their growth and spread.
Kadcyla 100 mg Injection is a targeted cancer therapy with a chemotherapy component, designed to deliver treatment specifically to HER2-positive cancer cells while minimizing damage to healthy cells.
Kadcyla 100 mg Injection is not a cure, but it helps control cancer progression, shrink tumors, and improve survival outcomes in patients with HER2-positive breast cancer.
Patients should monitor for liver problems, low platelet count, heart issues, and infusion reactions, and report any unusual symptoms to their doctor immediately.
Kadcyla 100 mg Injection is given as an intravenous infusion by a healthcare professional, usually in a hospital or clinical setting.
Kadcyla 100 mg Injection is not recommended during pregnancy due to potential harm to the fetus, and breastfeeding should be avoided during treatment.
Yes, doctors will regularly check liver function, heart function, and platelet counts to ensure the treatment is safe and effective.
Kadcyla 100 mg Injection is used for the treatment of HER2-positive breast cancer, especially in patients with advanced or metastatic disease or those who have not responded to previous therapies.
Kadcyla 100 mg Injection combines trastuzumab (a targeted antibody) with emtansine (a chemotherapy agent) to directly attack HER2-positive cancer cells, helping to stop their growth and spread.
Kadcyla 100 mg Injection is a targeted cancer therapy with a chemotherapy component, designed to deliver treatment specifically to HER2-positive cancer cells while minimizing damage to healthy cells.
Kadcyla 100 mg Injection is not a cure, but it helps control cancer progression, shrink tumors, and improve survival outcomes in patients with HER2-positive breast cancer.
Patients should monitor for liver problems, low platelet count, heart issues, and infusion reactions, and report any unusual symptoms to their doctor immediately.
Kadcyla 100 mg Injection is given as an intravenous infusion by a healthcare professional, usually in a hospital or clinical setting.
Kadcyla 100 mg Injection is not recommended during pregnancy due to potential harm to the fetus, and breastfeeding should be avoided during treatment.
Yes, doctors will regularly check liver function, heart function, and platelet counts to ensure the treatment is safe and effective.
Kadcyla 100 mg Injection is a targeted cancer therapy that contains the active ingredient Ado-Trastuzumab emtansine, specifically used for the treatment of HER2-positive breast cancer. It is prescribed for patients whose cancer has either spread to other parts of the body (metastatic breast cancer) or has not responded adequately to previous treatments. Kadcyla is a unique combination of two components—trastuzumab, a monoclonal antibody that targets HER2 receptors on cancer cells, and emtansine, a chemotherapy agent that works to destroy those cells. By directly targeting HER2-positive cancer cells, this medicine helps slow down tumor growth and improve treatment outcomes. It is also used in both early and advanced stages of breast cancer, especially in cases where the disease recurs within six months after chemotherapy.
Patients with residual cancer after chemotherapy and HER2-targeted therapy may have a higher risk of disease progression, making Kadcyla an important treatment option in such cases. While the medication is generally well tolerated and does not significantly affect kidney function, patients should remain alert for potential side effects. Some individuals may experience mild symptoms such as nausea, vomiting, diarrhea, or hair loss, while rare cases of infusion-related reactions or allergic responses may occur. It is important to report any unusual symptoms, including bleeding or severe reactions, to a healthcare provider immediately. Regular monitoring and medical supervision help ensure the safe and effective use of Kadcyla 100 mg Injection.
Kadcyla 100 mg Injection is primarily used in the treatment of HER2-positive cancers, especially in patients with advanced and metastatic breast cancer, where the cancer has spread beyond the breast to other parts of the body. It is also used in cases where the disease has not responded adequately to previous therapies, helping to control tumor growth and improve patient outcomes. In addition, Kadcyla may be used in the management of metastatic gastric (stomach) cancer that overexpresses the HER2 protein, offering a targeted treatment approach for better disease control.
Like other anticancer medicines, Kadcyla 100 mg Injection may cause side effects, which can be mild or serious depending on the patient’s condition and response to treatment.
If you experience any severe or unusual symptoms, seek immediate medical attention.
1. Do not use if you are allergic to Ado-Trastuzumab emtansine or any of its components.
2. May cause liver toxicity; regular liver function monitoring is required.
3. Can lead to low platelet count (thrombocytopenia), increasing the risk of bleeding
4. Use with caution in patients with heart problems, as it may affect heart function.
5. Infusion-related or allergic reactions may occur during or after administration.
6. Not recommended during pregnancy, as it may harm the unborn baby; use effective contraception.
7. Inform your doctor about all medications, supplements, or medical conditions before starting treatment.
8. Store in a refrigerator (2°C to 8°C).
9. Do not freeze or shake the vial.
10. Keep in the original packaging to protect from light.
Kadcyla 100 mg Injection is used for the treatment of HER2-positive breast cancer, especially in patients with advanced or metastatic disease or those who have not responded to previous therapies.
Kadcyla 100 mg Injection combines trastuzumab (a targeted antibody) with emtansine (a chemotherapy agent) to directly attack HER2-positive cancer cells, helping to stop their growth and spread.
Kadcyla 100 mg Injection is a targeted cancer therapy with a chemotherapy component, designed to deliver treatment specifically to HER2-positive cancer cells while minimizing damage to healthy cells.
Kadcyla 100 mg Injection is not a cure, but it helps control cancer progression, shrink tumors, and improve survival outcomes in patients with HER2-positive breast cancer.
Patients should monitor for liver problems, low platelet count, heart issues, and infusion reactions, and report any unusual symptoms to their doctor immediately.
Kadcyla 100 mg Injection is given as an intravenous infusion by a healthcare professional, usually in a hospital or clinical setting.
Kadcyla 100 mg Injection is not recommended during pregnancy due to potential harm to the fetus, and breastfeeding should be avoided during treatment.
Yes, doctors will regularly check liver function, heart function, and platelet counts to ensure the treatment is safe and effective.
Abirapro may cause side effects and/or use impacts if administered with other medicines, vitamins, and herbal supplements. Before starting Abirapro, your doctor should be completely aware of your medical history, previous ongoing treatments and prescriptions. Specific precautions that need to be taken:
Yes. It is recommended that complete medical history be disclosed to your physician before starting treatment with Abirapro. An alternate medication is likewise recommended. Further, you need to necessarily disclose to your physician if you have:
The most common side effects are:
Persistence in any of the symptoms may lead to fatal side effects. Refer your doctor immediately if you suffer any such symptoms for alternate medicine or additional medication to curb them.
Abirapro is not a cancer treatment drug. It is a hormonal treatment to slow growth of prostate cancer in men.
Specific studies to prove its efficiency/cure in any other type of cancer is yet not available.
No. Self-medication is strictly prohibited. Abirapro is known to have serious side effects. Prior consultation by a cancer specialist is strongly recommended. Also patients with pre-existing medical conditions need to disclose their medical history top their doctors before starting treatment with Abirapro.
Consumption of alcohol during administration of Abirapro should be avoided. Though no studies support any reaction of the medicine with alcohol, doctor’s instructions should be sought before consumption.
Yes. Abirapro is advised to be taken empty stomach to curb the side effects of the medicine when taken with food. Adverse effects such as a high blood pressure, muscle weakness, paralysis, and breathing difficulties are common symptoms noticed if medicine is taken along with food. Interval of 1 hour before meal and 2 hours after meal is advised for administration of the medicine.
Yes. Low blood cell count is a symptom. However, it is advisable to bring it to the notice of your physician. Persistent low blood cell count may lead to serious side effects.
Yes. Usage of Abirapro often leads to low blood cell count. To continue taking the medicine during the treatment period, it is advisable to get a regular blood cell count done up.
Administration of Abirapro leads to side effects such as high blood pressure, fluid retention (having too much water in your body), or having reduced levels of potassium in your blood. The risk of the side effects can be fatal. In order to counteract the side-effects of Abirapro, your doctor advises prednisolone.
Swelling of feet and ankles is a serious side-effect to the medicine. Immediate referral of a doctor is advised to curb additional effects. Self-medication to overcome symptoms is strictly prohibited.
Abirapro is a hormonal treatment drug administered to males only undergoing treatment of prostate cancer. No definite study supports the use of Abirapro in pediatric patients or females for any other type of cancer.
Yes. Reduced sex drive (libido) is a common medicinal side effect noticed due to the presence of the compound Abiraterone.
Sourced from Manufacturers
Air Express Delivery
Trusted Medicines
Get Up to 85% Off
